Theranostics · 2019 · 35 citations · 29 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis PharmacologyApoptosis ResistanceChemotherapy In Hematologic MalignanciesCytotoxic ChemotherapyHematologic Malignancy TherapyTyrosine Kinase InhibitorsAcute Myeloid Leukemia TherapyFlt3 InhibitorsIntrinsic Resistance MechanismsMurine ModelsReactive Oxygen Species GenerationSynergistic Inhibitor EffectsTyrosine Kinase InhibitionTyrosine Kinase Inhibitor Therapy
: This study indicates that melatonin, alone or in combination with sorafenib, has potential to improve the therapeutic outcome of AML patients with FLT3-ITD mutation that merits further investigation.
29
Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text
Medicine, Genetics, Hematology +14
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 745 citations
Medicine, Genetics, Hematology +13
Susan P. Whitman, Kellie J. Archer, Claudia D. Baldus et al. · PubMed · 2001 · 638 citations
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 474 citations
Medicine, Oncology, Pharmacology +11